Pharma companies could develop multiple small molecule drugs for related indications, rather than focus on a single molecule, to allow for staggered launch dates that would protect some uses from Medicare price negotiation beginning nine years after approval, Eli Lilly and Company CEO David Ricks suggested during a JP Morgan webinar on the impact of the Inflation Reduction Act 14 June.
Key Takeaways
-
Pharmas could develop multiple molecules for different indications and stagger launch dates.
Ricks discussed three strategies that manufacturers might consider to ameliorate the impact of the nine-year timeline, which is industry’s top...







